MISSISSAUGA, ON, Oct. 3, 2012 /CNW/ - Genzyme, a Sanofi company fully supports the move by Health Canada to accelerate approval and access to orphan drugs, as well as information through Orphanet-Canada, for patients suffering from rare diseases. As a company dedicated to finding treatments and cures for these patients, Genzyme Canada applauds the Minister of Heath's focus on the needs of small patient populations throughout Canada affected by these diseases.
"Ensuring that patients suffering from diseases such as Fabry, Gaucher, Pompe and MPS have timely access to innovative therapies is crucial and the Minister's announcement today is a great first step in addressing those needs" says Genzyme Canada's General Manager Peter Brenders.
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.
Genzyme® is a registered trademark. All rights reserved.
For further information: